# Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT

> **NCT02988258** · PHASE1 · SUSPENDED · sponsor: **University College, London** · enrollment: 10 (estimated)

## Conditions studied

- Haematological Malignancies
- CMV Infection

## Interventions

- **GENETIC:** CMV-TCR transduced donor-derived T cells

## Key facts

- **NCT ID:** NCT02988258
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2013-07
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 10 (ESTIMATED)
- **Why stopped:** Protocol being re-written to allow inclusion of more patients
- **Last updated:** 2018-09-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02988258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02988258, "Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02988258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*